^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
Published date:
12/07/2021
Excerpt:
Dynamics of ALK rearrangement and resistance mutations during TKI therapy...while seven patients (ALK_06, 13, 18, 20, 25, 44, 62) showed increasing EML4-ALK fusion abundance upon progression on independent therapy lines (Supplementary Fig. 1).
DOI:
https://doi.org/10.1038/s41698-021-00239-3
Source:
Title:
Abstract 2991: Establishment of patient-derived cancer cell lines to elucidate the resistant mechanism of tyrosine kinase inhibitors
Published date:
05/15/2020
Excerpt:
...we have established six patient-derived cancer cells (PDCs) from NSCLC patients who were treated with various TKIs and thereafter experienced disease progression.
DOI:
10.1158/1538-7445.AM2020-2991
